Qube Research & Technologies Ltd
- SEC CIK
- 0001729829
- Latest filing
- Aug 14, 2026
AMLX holding history
Amylyx Pharmaceuticals, Inc. in every 13F filed by Qube Research & Technologies Ltd, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
AMLX overviewAll 13F holders of AMLXFull Q2 2026 holdings
- Shares (Q2 2026)
- 681,389
- Value
- $12.2M
- % of portfolio
- <0.1%
- Quarters held
- 14
- Since Q1 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 681,389 | $12.2M | <0.1% | −20,847−3.0% | Reduced | Holders |
| Q1 2026 | 702,236 | $9.76M | <0.1% | +289,363+70.1% | Added | Holders |
| Q4 2025 | 412,873 | $4.99M | <0.1% | +245,767+147.1% | Added | Holders |
| Q3 2025 | 167,106 | $2.27M | <0.1% | −270,920−61.9% | Reduced | Holders |
| Q2 2025 | 438,026 | $2.81M | <0.1% | −504,865−53.5% | Reduced | Holders |
| Q1 2025 | 942,891 | $3.34M | <0.1% | +162,325+20.8% | Added | Holders |
| Q4 2024 | 780,566 | $2.95M | <0.1% | +596,672+324.5% | Added | Holders |
| Q3 2024 | 183,894 | $595.8K | <0.1% | −605,233−76.7% | Reduced | Holders |
| Q2 2024 | 789,127 | $1.50M | <0.1% | −154,936−16.4% | Reduced | Holders |
| Q1 2024 | 944,063 | $2.68M | <0.1% | +461,464+95.6% | Added | Holders |
| Q4 2023 | 482,599 | $7.10M | <0.1% | +319,889+196.6% | Added | Holders |
| Q3 2023 | 162,710 | $2.98M | <0.1% | +38,530+31.0% | Added | Holders |
| Q2 2023 | 124,180 | $2.68M | <0.1% | +92,455+291.4% | Added | Holders |
| Q1 2023 | 31,725 | $930.8K | <0.1% | +31,725 | New | Holders |